Invitation for me by direct message from my LinkedIn contact at LinkedIn to participate at 3rd International Conference on Gastroenterology in London, UK. Date: October 21-22, 2019. THEME: PRE-EMINENT ADVANCEMENT AND THERAPIES IN GASTROENTEROLOGY @& Many cancer drugs aim at the wrong molecular targets – Analysis using CRISPR gene-editing technology suggests that drugs’ mechanism of action are misunderstood.

  1. nature
  2. news
  3. article

a nature research journalMENU

SubscribeSearchLoginNEWS  11 SEPTEMBER 2019

Many cancer drugs aim at the wrong molecular targets

Analysis using CRISPR gene-editing technology suggests that drugs’ mechanism of action are misunderstood.

Heidi Ledford

Lung cancer cells dividing, coloured scanning electron micrograph (SEM).
Many cancer drugs seek to stop malignant cells, such as these lung-cancer cells, from proliferating.Credit: Anne Weston, EM STP, The Francis Crick Institute/Science Photo Library

Many experimental cancer drugs might be succeeding in unintended ways, finds a study that used CRISPR–Cas9 gene editing to investigate how such drugs interact with malignant cells.

An analysis of ten drugs — including seven now in clinical trials — found that the proteins they target are not crucial for the survival of cancer cells. The results could help to explain why many cancer drugs fail in clinical trials, says William Kaelin, a cancer researcher at the Dana–Farber Cancer Institute in Boston, Massachusetts. Still, he says, “I’m not terribly surprised by the findings.”

The results, published in Science Translational Medicine1 on 11 September, do not necessarily mean that the drugs will not work at all. Some might have shown signs of success in early trials because they are acting on other, unknown targets, says the study’s lead author, cancer geneticist Jason Sheltzer of Cold Spring Harbor Laboratory in New York.

But not knowing drugs’ true mode of action could limit their prospects, he adds. In some cases, scientists can link a therapy to a molecular marker that indicates how likely that drug is to work in a given person. Scientists can then use these markers to select clinical-trial participants who are likely to benefit from the therapy, boosting the chances that it will succeed in the tests used to seek regulatory approval.

This approach is not possible if the drug’s target is uncertain, Sheltzer says. And drugs with unknown targets could harm normal cells in addition to cancer cells, raising the risk of toxic side effects.

“It’s hard enough to develop drugs when you know their mechanism of action,” says Kaelin. “It’s really difficult when you don’t know the mechanism of action.”

Missing the target

Sheltzer and his lab first stumbled onto the problem by accident: in search of a positive control for an experiment, they selected a well-studied protein thought to be important in breast-cancer cell division. But when the team used CRISPR–Cas9 to mutate the gene that controls production of the protein2they found no effect on cancer-cell growth. “We wanted to know whether that was just kind of a one-off occurrence, or whether there were other genes like it in clinical trials,” he says.

The researchers then selected ten other drugs, targeting a total of six proteins, for further evaluation. The ten drugs have been used in 29 clinical trials that aim to enrol more than 1,000 people; their protein targets have been implicated in cancer-cell survival and proliferation in over 180 publications.

But much of the evidence in support of those targets came from a technique called RNA-interference (RNAi), which allows researchers to silence specific genes — but can sometimes affect the activity of other genes.

Sheltzer’s team used multiple methods to evaluate the relationship between the drugs’ efficacy and their targets. They included CRISPR–Cas9, which disables genes in a different way — by editing them to create mutations in them. Some studies have suggested that CRISPR is more precise than RNAi, although it too can sometimes affect other genes.

Homing in

In each case, they found that the target of the ten experimental cancer drugs did not affect the growth of cancer cells grown in the laboratory, compared to controls. Furthermore, when the scientists used CRISPR to wipe out expression of proteins targeted by the drugs, the therapies still killed cancer cells. This suggests that the drugs’ effectiveness is not tied to their purported protein targets after all.

The team then examined one drug, OTS964, in more detail. They found that, although the drug had been developed to target one protein, it was exerting its effect on cancer cells through another ― CDK11, which is involved in cell division.

The findings do have limitations, notes study co-author Ann Lin, a cancer researcher at Stanford University in California. Her team′s experiments were carried out in cells grown in the lab, she notes. “It is possible that these drug targets are essential in human patients,” she says, and not in isolated cells.

And Kaelin says that there was little prior genetic data on the collection of drugs and targets that the team examined — making it hard to back up their value in mice or people. Other targets, with stronger evidence to back them up, would likely fare better, he says.

But Sheltzer hopes to use his results to track down other proteins, like CDK11, that could be exploited for new cancer treatments. “There is an unexplored world of cancer targets out there,” he says. “By using CRISPR and other technologies to examine these drugs, we might unlock new targets.”doi: 10.1038/d41586-019-02701-6


  1. 1.Lin, A. et al. Sci. Transl. Med. 11, eaaw8412 (2019).
  2. 2.Lin, A., Giuliano, C. J., Sayles, N. M. & Sheltzer, J. M. eLife 6, e24179 (2017).

Download referencesshow more

Latest on:


Drug discoveryCancer cells have ‘unsettling’ ability to hijack the brain’s nervesNEWS 18 SEP 19Synaptic proximity enables NMDAR signalling to promote brain metastasisARTICLE 18 SEP 19Electrical and synaptic integration of glioma into neural circuitsARTICLE 18 SEP 19

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.Email addressYes! Sign me up to receive the daily Nature Briefing email. I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy.Sign up



Get the most important science stories of the day, free in your inbox.Sign up for Nature BriefingClose


ISSN 1476-4687 (online)

Nature Research

Discover content

Publish with us

Researcher services

Libraries & institutions

Advertising & partnerships

Career development

Regional websites

Springer Nature


  1. Hello

    Tired of Waiting FOREVER to earn a profit online?

    I’m talking about a new way to generate quick traffic and sales in ANY niche with ZERO video/website creation, ZERO paid advertising/SEO. I’ve recently tried this product but quickly decide to write this review because I know this is exactly what you guys are looking for.

    No Previous Skills Or Experience Required. You can literally be a COMPLETE Newbie and Get RESULTS with just 5 minutes of actual “work”..


    And Of Course, You Also Have A 30-DAY, YOUR-MONEY Back GUARANTEE
    Once you Join TODAY, You’ll Also GET AMAZING BONUSES



  2. Hello. I have checked your and i see
    you’ve got some duplicate content so probably it is the reason that you don’t rank hi
    in google. But you can fix this issue fast.
    There is a tool that creates articles like human,
    just search in google: miftolo’s tools


  3. Nice post. I learn something tougher on completely different blogs everyday. It can at all times be stimulating to learn content from different writers and follow slightly one thing from their store. I’d want to make use of some with the content on my weblog whether you don’t mind. Natually I’ll offer you a hyperlink in your internet blog. Thanks for sharing.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s